Kiadis Pharma N : Corporate Presentation March 2021

KIADIS PHARMA | COMPANY PRESENTATION | MARCH 2021

EURONEXT: KDS

Leveraging the natural strengths of humanity and our collective immune systems to source the best cells for life

K-NK-cell therapy to treat cancer and infectious disease

The future of immunotherapy: enough of the right NK cells

CAR-TCAR-NKK-NK & CAR-K-NK

FunctionalityBreadthManufacturingSafetyPotent and persistent, repeat dosing

Across indications, heterogeneous disease/escape

Industrial, scalable and off-the-shelf

Suitable for mass usage

•   

•  

K-NK: enough of the right NK cells

Uniquely potent immunotherapy platform:

• • Hyper-functional K-NK-cell phenotype

• • Sourced from optimal donors with disease specific attributes

• • Engineering synergistic, but not requiredOff the shelf, industrial, scalable

• • Industrial, robust, tumor-free

• • Millions of doses, cryopreserved

• • Cost of goods competitive to antibodyProof-of-concept in 49 immuno-compromised blood cancer patients

• • Anti-tumor: Remarkable remissions; Improvement in relapse and survival

• • Anti-infective: Efficacy against viral, fungal and bacterial agents

• • No safety event (no CRS, no GVHD, no serious AE)

• • Repeat dosing, persistence and proliferation in patients

KIADIS PHARMA |www.kiadis.com| CONFIDENTIAL

3

Pipeline in cancer and infectious disease

PROGRAM	INDICATION	SETTING	PRODUCT	PRE-CLINICAL	CLINICAL PoC	CLINICAL	STATUS
PH. 1	PH. 2
K-NK002	HSCT in blood cancer	Adjunctive to SoC (PTCy)	Haplo	24 patients	Phase 2 with US BMT-CTN; IND approved
K-NK003	AML R/R	After induction chemo (FLAG)	OTS	25 patients	Phase 1/2a with US OSU; enrolling patients
K-NK004	Multiple myeloma	Combination with Sarclisa	OTS CD38KO	Partnership Sanofi; value >€875 million
K-NK-ID101	Influenza / COVID-19	Prophylaxis & treatment	OTS-ID	Ph 1/2a IST IND approved; funded by US DoD
K-NK00X	Other	Stand alone or combo's	OTS-X	Studies to start in 2021, e.g., CML, CRC, HNC